evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

122 questions · 122 findings · 14 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 22 · 18%GRADE not reported 5 · 4.1%Very low 18 · 14.8%Low 37 · 30.3%Moderate 34 · 27.9%High 6 · 4.9%

Certolizumab pegol vs placebo

Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).

1 finding from 1 review

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Sustained virological response · patients on HD with HCV infection

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

1 finding from 1 review

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

End‐of‐treatment response · patients on HD with HCV infection

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in HAQ change from baseline Scale from: 0 to 3. compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

DAS (low or remission) · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher proportion of patients achieving DAS < 2.6 (remission) compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in radiological changes: Erosion Scores (ES) Scale from: 0 to 230 compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher hypersensitivity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher pancreatitis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in osteonecrosis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review